KRTX Karuna Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

KRTX [NASD]

Karuna Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.67	Insider Own	13.20%	Shs Outstand	26.19M	Perf Week	-4.08%
Market Cap	2.01B	Forward P/E	-	EPS next Y	-3.96	Insider Trans	-40.61%	Shs Float	22.74M	Perf Month	0.29%
Income	-42.50M	PEG	-	EPS next Q	-0.82	Inst Own	83.80%	Short Float	5.99%	Perf Quarter	-27.44%
Sales	-	P/S	-	EPS this Y	-106.20%	Inst Trans	10.17%	Short Ratio	7.42	Perf Half Y	7.79%
Book/sh	14.20	P/B	5.43	EPS next Y	-39.90%	ROA	-12.80%	Target Price	126.50	Perf Year	373.01%
Cash/sh	14.12	P/C	5.46	EPS next 5Y	-	ROE	-13.00%	52W Range	11.24 - 152.00	Perf YTD	2.34%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-49.28%	Beta	-
Dividend %	-	Quick Ratio	92.10	Sales past 5Y	-	Gross Margin	-	52W Low	585.94%	ATR	3.71
Employees	19	Current Ratio	92.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.80	Volatility	4.03% 4.92%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-0.70%	Profit Margin	-	Rel Volume	0.59	Prev Close	77.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	183.47K	Price	77.10
Recom	1.50	SMA20	-0.98%	SMA50	-6.78%	SMA200	-9.40%	Volume	109,086	Change	0.00%

Aug-06-20

Reiterated

H.C. Wainwright

Buy

$140 → $130

May-28-20

Initiated

H.C. Wainwright

Buy

$140

Apr-28-20

Initiated

Oppenheimer

Outperform

$125

Mar-31-20

Initiated

Guggenheim

Buy

$120

Mar-24-20

Resumed

Wedbush

Outperform

$124

Feb-06-20

Initiated

Mizuho

Buy

Jan-09-20

Initiated

JMP Securities

Mkt Outperform

$122

Dec-19-19

Initiated

Stifel

Buy

$126

Dec-12-19

Initiated

William Blair

Outperform

$105

Jul-23-19

Initiated

Wells Fargo

Outperform

$29

Jul-23-19

Initiated

Wedbush

Outperform

$38

Jul-23-19

Initiated

Goldman

Buy

$34

Jul-23-19

Initiated

Citigroup

Buy

$28

Sep-22-20 10:22AM	Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation Simply Wall St.
Sep-21-20 09:56AM	A Look Into Healthcare Sector Value Stocks Benzinga -5.10%
Sep-03-20 06:30AM	Karuna Therapeutics to Present at Upcoming Investor Conferences Business Wire
Aug-17-20 11:46AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Aug-13-20 06:30AM	Karuna Therapeutics Appoints Laurie Olson to Board of Directors Business Wire
Aug-05-20 06:00AM	Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights Business Wire
Aug-03-20 04:30PM	Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers Business Wire +7.14%
Jul-30-20 06:30AM	Karuna Therapeutics to Present at Upcoming Investor Conferences Business Wire
Jul-28-20 06:30AM	Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration Business Wire
Jun-28-20 07:14PM	Hedge Funds Keep Buying Karuna Therapeutics, Inc. (KRTX) Insider Monkey
Jun-24-20 08:56AM	Karuna Therapeutics, Inc. (NASDAQ:KRTX) Insiders Increased Their Holdings Simply Wall St.
Jun-23-20 06:30AM	Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia Business Wire
Jun-03-20 06:30AM	Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Business Wire +5.62%
May-27-20 06:30AM	Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting Business Wire
May-20-20 09:17AM	Why You Shouldn't Bet Against Karuna Therapeutics (KRTX) Stock Zacks
08:48AM	Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX) Zacks
May-07-20 06:00AM	Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update Business Wire
Apr-28-20 06:00AM	Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors Business Wire
Apr-27-20 10:09AM	The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education Zacks
Apr-22-20 10:55AM	Karuna Therapeutics, Inc. (KRTX) Shares March Higher, Can It Continue? Zacks
Apr-07-20 05:18PM	Hedge Funds Have Never Been This Bullish On Karuna Therapeutics, Inc. (KRTX) Insider Monkey
Mar-31-20 08:35AM	Why You Shouldn't Bet Against Karuna Therapeutics (KRTX) Stock Zacks
Mar-26-20 07:00AM	Karuna Therapeutics to Participate in Stifels 2nd Annual CNS Day Virtual Event Business Wire +5.75%
Mar-24-20 06:00AM	Karuna Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Provides General Business Update Business Wire
Feb-25-20 07:00AM	Karuna Therapeutics to Present at the Cowen and Company's 40th Annual Health Care Conference Business Wire -8.04%
Feb-06-20 07:00AM	Karuna Therapeutics Provides Update on its Discovery Research Efforts Business Wire
Jan-12-20 02:36PM	Top Insider Buys Highlight for the Week of Jan. 10 GuruFocus.com
Jan-09-20 08:00AM	Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-19 09:17AM	The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK Zacks -7.25%
Dec-26-19 09:53AM	5 Best Performing IPOs of 2019 Zacks +7.56%
Dec-23-19 02:47PM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch -5.04%
Dec-20-19 12:38PM	Years Best U.S. IPO Is a Little-Known Biotech With 420% Surge Bloomberg +10.15%
Dec-19-19 09:53PM	Is Karuna Therapeutics, Inc. (KRTX) A Good Stock To Buy ? Insider Monkey +12.41%
Dec-10-19 03:17AM	Karuna Therapeutics Shares March Higher, Can It Continue? Zacks
Nov-26-19 07:00AM	Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases -11.32%
07:00AM	Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-20-19 06:58PM	Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock Business Wire -12.13%
09:31AM	Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
Nov-19-19 04:20PM	Here's Why This Biotech Stock Has Septupled In Value Over Two Days Investor's Business Daily +29.16%
09:54AM	Company News For Nov 19, 2019 Zacks
07:56AM	The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
05:51AM	Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News Investor's Business Daily
Nov-18-19 04:21PM	Karuna Therapeutics Announces Proposed Public Offering of Common Stock Business Wire +442.99%
11:18AM	Karuna Therapeutics' stock more than triples after upbeat trial results of schizophrenia treatment MarketWatch
06:00AM	Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia Business Wire
Nov-17-19 04:00PM	Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia Business Wire
Nov-07-19 06:00AM	Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update Business Wire
Aug-28-19 08:00AM	Karuna Therapeutics to Present at Upcoming Investor Conferences Business Wire
Aug-08-19 06:00AM	Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update Business Wire +7.47%
Aug-06-19 08:00AM	Karuna Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire -7.54%
Jul-02-19 07:15PM	Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares GuruFocus.com
04:01PM	Karuna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Jun-28-19 11:32AM	Karuna Therapeutics Opens Above IPO Price Benzinga
Jun-27-19 05:44PM	Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering Business Wire
04:37PM	Karuna Therapeutics IPO: What You Need To Know Benzinga

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pande Atul	Director	Sep 16	Option Exercise	2.92	5,000	14,600	5,000	Sep 18 04:09 PM
Pande Atul	Director	Sep 16	Sale	85.00	5,000	425,000	0	Sep 18 04:09 PM
Miller Andrew Craig	Chief Operating Officer	Sep 10	Option Exercise	7.27	5,000	36,350	38,000	Sep 10 05:18 PM
Miller Andrew Craig	Chief Operating Officer	Sep 10	Sale	75.52	5,000	377,600	33,000	Sep 10 05:18 PM
HEALY JAMES	Director	Sep 09	Buy	73.75	4,557	336,079	1,952,441	Sep 11 10:22 AM
Ignelzi Troy A.	Chief Financial Officer	Sep 08	Option Exercise	9.20	2,000	18,400	7,000	Sep 10 05:15 PM
HEALY JAMES	Director	Sep 08	Buy	73.00	504	36,792	1,947,884	Sep 09 05:04 PM
Ignelzi Troy A.	Chief Financial Officer	Sep 08	Sale	73.30	2,000	146,600	5,000	Sep 10 05:15 PM
Preston Heather	Director	Sep 04	Buy	72.36	350	25,326	5,800	Sep 09 08:10 PM
HEALY JAMES	Director	Sep 04	Buy	71.73	61,778	4,431,116	1,947,380	Sep 09 05:04 PM
PureTech Health LLC	10% Owner	Aug 26	Sale	76.21	1,333,333	101,616,241	3,406,564	Aug 26 05:15 PM
Ignelzi Troy A.	Chief Financial Officer	Aug 25	Option Exercise	9.20	5,000	46,000	5,000	Aug 27 05:58 PM
Pande Atul	Director	Aug 12	Option Exercise	2.92	5,000	14,600	5,000	Aug 14 04:16 PM
Pande Atul	Director	Aug 12	Option Exercise	2.92	5,000	14,600	5,000	Aug 14 04:19 PM
Pande Atul	Director	Aug 12	Sale	85.00	5,000	425,000	0	Aug 14 04:16 PM
HARRIGAN EDMUND	Director	Aug 12	Sale	83.32	10,000	833,200	55,163	Aug 14 04:13 PM
Pande Atul	Director	Aug 12	Sale	85.00	5,000	425,000	0	Aug 14 04:19 PM
Pande Atul	Director	Jul 13	Option Exercise	2.92	5,000	14,600	5,000	Jul 13 04:49 PM
Pande Atul	Director	Jul 13	Sale	95.43	5,000	477,150	0	Jul 13 04:49 PM
HARRIGAN EDMUND	Director	Jul 13	Sale	93.40	10,000	934,000	65,163	Jul 13 04:48 PM
Ignelzi Troy A.	Chief Financial Officer	Jul 08	Option Exercise	9.20	8,000	73,600	8,000	Jul 10 09:21 PM
Ignelzi Troy A.	Chief Financial Officer	Jul 08	Sale	98.74	8,000	789,920	0	Jul 10 09:21 PM
Brannan Stephen K.	Chief Medical Officer	Jul 01	Option Exercise	8.28	10,228	84,723	22,728	Jul 02 04:03 PM
Brannan Stephen K.	Chief Medical Officer	Jul 01	Sale	108.53	7,728	838,720	15,000	Jul 02 04:03 PM
PAUL STEVEN M	PRESIDENT & CEO	Jun 29	Option Exercise	0.11	292,207	32,143	398,692	Jun 30 04:25 PM
PAUL STEVEN M	PRESIDENT & CEO	Jun 29	Sale	103.50	292,207	30,243,425	106,485	Jun 30 04:25 PM
Miller Andrew Craig	Chief Operating Officer	Jun 16	Option Exercise	9.20	8,334	76,673	41,334	Jun 16 05:00 PM
Ignelzi Troy A.	Chief Financial Officer	Jun 16	Option Exercise	9.20	2,000	18,400	2,000	Jun 17 04:40 PM
Ignelzi Troy A.	Chief Financial Officer	Jun 16	Sale	100.00	2,000	200,000	0	Jun 17 04:40 PM
Miller Andrew Craig	Chief Operating Officer	Jun 16	Sale	97.58	8,334	813,232	33,000	Jun 16 05:00 PM
Miller Andrew Craig	Chief Operating Officer	Jun 15	Option Exercise	4.02	41,333	166,132	37,762	Jun 16 05:00 PM
Ignelzi Troy A.	Chief Financial Officer	Jun 15	Option Exercise	9.20	6,000	55,200	4,000	Jun 17 04:40 PM
Ignelzi Troy A.	Chief Financial Officer	Jun 15	Sale	89.75	6,000	538,480	0	Jun 17 04:40 PM
Miller Andrew Craig	Chief Operating Officer	Jun 15	Sale	92.38	8,333	769,803	33,000	Jun 16 05:00 PM
Miller Andrew Craig	Chief Operating Officer	Jun 12	Option Exercise	8.05	8,333	67,075	37,968	Jun 16 05:00 PM
Pande Atul	Director	Jun 12	Option Exercise	2.92	5,000	14,600	5,000	Jun 15 05:19 PM
HARRIGAN EDMUND	Director	Jun 12	Sale	91.79	30,000	2,753,700	75,163	Jun 15 05:20 PM
Pande Atul	Director	Jun 12	Sale	93.27	5,000	466,350	0	Jun 15 05:19 PM
Miller Andrew Craig	Chief Operating Officer	Jun 12	Sale	93.28	8,333	777,302	33,000	Jun 16 05:00 PM
Miller Andrew Craig	Chief Operating Officer	Jun 01	Option Exercise	7.27	25,000	181,750	25,000	Jun 02 04:34 PM
Brannan Stephen K.	Chief Medical Officer	Jun 01	Option Exercise	6.83	10,228	69,808	20,228	Jun 02 04:35 PM
Miller Andrew Craig	Chief Operating Officer	Jun 01	Sale	90.64	25,000	2,266,000	0	Jun 02 04:34 PM
Brannan Stephen K.	Chief Medical Officer	Jun 01	Sale	90.64	7,728	700,466	12,500	Jun 02 04:35 PM
PureTech Health LLC	10% Owner	May 22	Sale	81.03	555,500	45,014,750	4,739,897	May 26 06:05 AM
Ignelzi Troy A.	Chief Financial Officer	May 08	Option Exercise	9.20	7,500	69,000	7,500	May 12 04:33 PM
Ignelzi Troy A.	Chief Financial Officer	May 08	Sale	83.38	7,500	625,350	0	May 12 04:33 PM
Brannan Stephen K.	Chief Medical Officer	May 01	Option Exercise	5.45	10,228	55,743	17,728	May 04 04:33 PM
Miller Andrew Craig	Chief Operating Officer	May 01	Option Exercise	7.27	25,000	181,750	25,000	May 04 04:32 PM
Miller Andrew Craig	Chief Operating Officer	May 01	Sale	76.98	25,000	1,924,500	0	May 04 04:32 PM
Brannan Stephen K.	Chief Medical Officer	May 01	Sale	79.38	7,728	613,449	10,000	May 04 04:33 PM
Brannan Stephen K.	Chief Medical Officer	Apr 01	Option Exercise	8.28	10,228	84,723	15,228	Apr 03 05:06 PM
Miller Andrew Craig	Chief Operating Officer	Apr 01	Option Exercise	5.42	25,000	135,405	14,346	Apr 03 05:07 PM
Miller Andrew Craig	Chief Operating Officer	Apr 01	Sale	64.37	25,000	1,609,250	0	Apr 03 05:07 PM
Brannan Stephen K.	Chief Medical Officer	Apr 01	Sale	67.36	7,728	520,558	7,500	Apr 03 05:06 PM
Preston Heather	Director	Mar 12	Buy	71.71	2,050	146,998	5,450	Mar 12 06:34 PM
Preston Heather	Director	Mar 10	Buy	80.00	1,000	80,000	3,400	Mar 12 06:34 PM
Miller Andrew Craig	Chief Operating Officer	Mar 02	Option Exercise	2.92	25,000	73,000	17,857	Mar 04 04:35 PM
Brannan Stephen K.	Chief Medical Officer	Mar 02	Option Exercise	6.83	10,228	69,808	12,728	Mar 04 04:38 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 02	Option Exercise	9.20	7,500	69,000	7,500	Mar 04 04:42 PM
Ignelzi Troy A.	Chief Financial Officer	Mar 02	Sale	86.50	7,500	648,750	0	Mar 04 04:42 PM
Brannan Stephen K.	Chief Medical Officer	Mar 02	Sale	86.55	7,728	668,858	5,000	Mar 04 04:38 PM
Miller Andrew Craig	Chief Operating Officer	Mar 02	Sale	86.61	25,000	2,165,250	0	Mar 04 04:35 PM
Brannan Stephen K.	Chief Medical Officer	Feb 19	Option Exercise	5.45	10,228	55,743	10,228	Feb 20 04:25 PM
Brannan Stephen K.	Chief Medical Officer	Feb 19	Sale	101.63	7,728	785,397	2,500	Feb 20 04:25 PM
PureTech Health LLC	10% Owner	Jan 22	Sale	95.67	2,100,000	200,907,000	5,295,397	Jan 24 04:40 PM
Preston Heather	Director	Jan 09	Buy	70.50	788	55,554	2,400	Jan 10 04:48 PM
Preston Heather	Director	Jan 03	Buy	69.80	1,427	99,601	1,612	Jan 07 06:09 PM
Preston Heather	Director	Dec 31	Buy	70.00	185	12,950	185	Jan 03 05:13 PM
HEALY JAMES	Director	Nov 25	Buy	96.00	156,250	15,000,000	1,885,602	Nov 25 09:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience